- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00453856
Efficacy of Sulfadoxine-Pyrimethamine for Treating Malaria in Gabonese Children
Efficacy of Sulfadoxine-Pyrimethamine in the Treatment of Symptomatic, Uncomplicated Plasmodium Falciparum Malaria Among 6-59 Month Old Children in Lambaréné
IPTi, a strategy whereby infants are provided treatment doses of antimalarials at routine vaccination visits, has been shown to significantly reduce malaria and anemia in two studies in Tanzania. However the results obtained in Gabon are not similar. Many factors are likely to influence the efficacy or effectiveness IPTi. It is reasonable to assume that the efficacy of IPTi will be influenced markedly by the sensitivity of Plasmodium falciparum to the antimalarial drug (Sulfadoxine-Pyrimethamine) used for IPTi.
In order to interpret the results of individual IPTi trials conducted by the IPTi Consortium, and to provide information for policy makers regarding the predicted efficacy of IPTi, it is essential to obtain information on antimalarial drug sensitivity of Sulfadoxine-Pyrimethamine now that the IPTi trial has been conducted. The simplest and most universally accepted measure of testing for antimalarial drug efficacy is the "in vivo efficacy study," which follows a standardized World Health Organization protocol.
A second reason for evaluating drug resistance as an adjunct to the IPTi trials is to determine if the intervention increases the carriage and/or spread of drug resistant P. falciparum parasites.
Thirdly the overall effect at the community level of selection of resistant genotypes in IPTi-recipients is unclear.
Descripción general del estudio
Descripción detallada
Administration of standard single oral dose of sulfadoxine-pyrimethamine to children aged 6-59 month old children in Lambaréné at enrolment, if eligible according to the approved protocol.
139 subjects will be enrolled and treated with Sulfadoxine-Pyrimethamine for uncomplicated malaria. Thereafter each subject will be followed according to the approved protocol
The proportion of subjects with Adequate Clinical and Parasitological response (ACPR) by day 28, Early Treatment Failure (ETF), Late Clinical Failure (LCF) and Late Parasitological Failure (LPF)will be evaluated.
secondly the frequency of molecular markers for Sulfadoxine-Pyrimethamine drug resistance will be determined.
Tipo de estudio
Inscripción (Anticipado)
Fase
- Fase 4
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Moyen Ogooué
-
Lambaréné, Moyen Ogooué, Gabón, B.P. 118
- Medical Research Unit of the Albert Schweitzer Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Male and female outpatients
- Aged 6 to 59 months
- Body weight between 7.5 to 30 kg
- uncomplicated falciparum malaria with parasitaemia between 1,000/µL and 200,000/µL
- Ability to tolerate oral therapy
- Informed consent, oral agreement of the child if appropriate
Exclusion Criteria:
- Still in IPTi trial and/or still in any other intervention trial
- Known G6PD-deficiency
- Presence of severe malnutrition
- Inability to drink or breastfeed
- Recent history of convulsions, lethargy or unconsciousness;
- Signs of severe and complicated
- Mixed/mono infection that includes a non-P. falciparum species.
- Hb < 7g/dl
- Inability to attend stipulated follow-up visits.
- History of hypersensitivity reactions to the drug being evaluated
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
---|
Measure the clinical and parasitological efficacy of SP among patients aged between 6-59 months suffering from uncomplicated P falciparum malaria,
|
Medidas de resultado secundarias
Medida de resultado |
---|
Determine the frequency of molecular markers for drug resistance
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Director de estudio: Martin P Grobusch, MD, Medical Research Unit, Albert Schweitzer Hospital Lambaréné
- Investigador principal: Saadou Issifou, MD MSc, Albert Schweitzer Hospital
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Infecciones
- Enfermedades transmitidas por vectores
- Enfermedades parasitarias
- Infecciones por protozoos
- Malaria
- Mecanismos moleculares de acción farmacológica
- Agentes antiinfecciosos
- Inhibidores de enzimas
- Agentes antiprotozoarios
- Agentes antiparasitarios
- Antipalúdicos
- Antagonistas del ácido fólico
- Agentes Antiinfecciosos Urinarios
- Agentes renales
- Pirimetamina
- Sulfadoxina
- Fanasil, combinación de drogas de pirimetamina
Otros números de identificación del estudio
- IPTi-DRWG- SP Lambaréné
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .